Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
Respiratory syncytial virus (RSV) infection occurs commonly in infants aged ≤2 years, and severe infection results in hospitalization with accompanying morbidity and mortality. Palivizumab has been available for prophylaxis for the past 15 years. Prospective data on patients who received palivizumab...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/917068 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849410685492002816 |
|---|---|
| author | Bosco Paes Ian Mitchell Abby Li Tetsuhiro Harimoto Krista L. Lanctôt |
| author_facet | Bosco Paes Ian Mitchell Abby Li Tetsuhiro Harimoto Krista L. Lanctôt |
| author_sort | Bosco Paes |
| collection | DOAJ |
| description | Respiratory syncytial virus (RSV) infection occurs commonly in infants aged ≤2 years, and severe infection results in hospitalization with accompanying morbidity and mortality. Palivizumab has been available for prophylaxis for the past 15 years. Prospective data on patients who received palivizumab from 2005 to 2012 has been assembled in the Canadian registry (CARESS) to document utilization, compliance, and health outcomes in both hospital and community settings. Long-term data is necessary to evaluate the impact of palivizumab on the incidence of RSV infections, minimize healthcare resources, and identify which infant subpopulations are receiving prophylaxis. A database search was also conducted for similar information from published registries, and hospitalization rates were compared to results from randomized clinical trials (RCTs).Overall hospitalization rates (percent; range) for respiratory-related illnesses and RSV-specific infection in infants who meet standard indications for prophylaxis were 6.6 (3.3–7.7) and 1.55 (0.3–2.06), respectively, in CARESS, which closely aligns with registry data from 4 other countries, despite the former comprising the largest cohort of complex patients internationally. Overall RSV-related hospitalization rates were lower across registries compared to equivalent patients in RCTs. Registry data provides valuable information regarding real-world experience with palivizumab, while facilitating the genesis of new research themes. |
| format | Article |
| id | doaj-art-5b3a7c3fefaa43568c5096760cb84503 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-5b3a7c3fefaa43568c5096760cb845032025-08-20T03:35:01ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/917068917068Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International RegistriesBosco Paes0Ian Mitchell1Abby Li2Tetsuhiro Harimoto3Krista L. Lanctôt4Department of Pediatrics, McMaster University, Hamilton, ON, L8S 4K1, CanadaDepartment of Pediatrics, University of Calgary, Calgary, AB, T3B 6A8, CanadaMedical Outcomes and Research in Economics (MORE) Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, CanadaMedical Outcomes and Research in Economics (MORE) Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, CanadaMedical Outcomes and Research in Economics (MORE) Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, CanadaRespiratory syncytial virus (RSV) infection occurs commonly in infants aged ≤2 years, and severe infection results in hospitalization with accompanying morbidity and mortality. Palivizumab has been available for prophylaxis for the past 15 years. Prospective data on patients who received palivizumab from 2005 to 2012 has been assembled in the Canadian registry (CARESS) to document utilization, compliance, and health outcomes in both hospital and community settings. Long-term data is necessary to evaluate the impact of palivizumab on the incidence of RSV infections, minimize healthcare resources, and identify which infant subpopulations are receiving prophylaxis. A database search was also conducted for similar information from published registries, and hospitalization rates were compared to results from randomized clinical trials (RCTs).Overall hospitalization rates (percent; range) for respiratory-related illnesses and RSV-specific infection in infants who meet standard indications for prophylaxis were 6.6 (3.3–7.7) and 1.55 (0.3–2.06), respectively, in CARESS, which closely aligns with registry data from 4 other countries, despite the former comprising the largest cohort of complex patients internationally. Overall RSV-related hospitalization rates were lower across registries compared to equivalent patients in RCTs. Registry data provides valuable information regarding real-world experience with palivizumab, while facilitating the genesis of new research themes.http://dx.doi.org/10.1155/2013/917068 |
| spellingShingle | Bosco Paes Ian Mitchell Abby Li Tetsuhiro Harimoto Krista L. Lanctôt Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries Clinical and Developmental Immunology |
| title | Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries |
| title_full | Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries |
| title_fullStr | Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries |
| title_full_unstemmed | Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries |
| title_short | Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries |
| title_sort | respiratory related hospitalizations following prophylaxis in the canadian registry for palivizumab 2005 2012 compared to other international registries |
| url | http://dx.doi.org/10.1155/2013/917068 |
| work_keys_str_mv | AT boscopaes respiratoryrelatedhospitalizationsfollowingprophylaxisinthecanadianregistryforpalivizumab20052012comparedtootherinternationalregistries AT ianmitchell respiratoryrelatedhospitalizationsfollowingprophylaxisinthecanadianregistryforpalivizumab20052012comparedtootherinternationalregistries AT abbyli respiratoryrelatedhospitalizationsfollowingprophylaxisinthecanadianregistryforpalivizumab20052012comparedtootherinternationalregistries AT tetsuhiroharimoto respiratoryrelatedhospitalizationsfollowingprophylaxisinthecanadianregistryforpalivizumab20052012comparedtootherinternationalregistries AT kristallanctot respiratoryrelatedhospitalizationsfollowingprophylaxisinthecanadianregistryforpalivizumab20052012comparedtootherinternationalregistries |